LETRONOL
Manufacturer Details
KNOLL INDIA
ABBOTT INDIA
Compositions:
Letrozole 2.5mg f.c.tablets,
|
Strength
|
Rate
|
Packing Style
|
|
2.5mg
|
175.00
|
5s f.c.tablets
|
List of Related Indications:
List Of Drugs:
- Letrozole - Aromatase Inhibitors- Hormones- (Mar 1998)
Indication Type Description:
Drug Interaction:
Plasma levels reduced by tamoxifen
Indication:
LIST OF DRUGS DURING 2007
Sr.No- 53
Name of the Drug- Letrozole 2.5mg tablet
(addl.stgth)
Pharmacological Classification- For induction of ovulation in anavulotory infertility
(addl.indcn)
Date of Approval- 10-04-07
Approved by U.S.FDA on 30-12-2007 (Ref- FDA approved List- 2007)
Advanced or locally advanced breast cancer
Adjuvant therapy for postmenopausal women with hormone receptor postive breast cancer
Approved by (DCI) Drug Controller GENERAL - India For Marketing
(Ref- IDMA Publication)
Name of Drug Indication Date of Approval
1.Letrozole Anti-cancer 12-03-1998
2.Letrozole 2.5mg tablet 10-04-2007
(Addl.stgth.)
For induction of ovulation in anovolatory infertility
INFORMATION- UPDATE
LETROZOLE - USE IN INFERTILITY BANNED
The drug Controller of India (DCGI ) has banned the use of Letrozole in the treatment of
female infertility. Globally the drug is approved for thetreatment of breast cancer in
post-menopausal women only.(MIMS)
Adverse Reaction:
Hotflushes, arthagia, nausea, vomiting Dizziness, headache
Dyspepsia, constiption Diarrhea Anorexia, alopoecia
Increasedsweating, rash Peripheral odema
Osteoporosis Musculoskeletal pain
Vaginal irritation Thromboembolitic events
Contra-Indications:
Premenopausal women and children Hypersensitivity
Special precautions-
Severe renal impairment Severe hepatic impairment Osteoporosi
Caution when driving or operating machinery
Dosages/ Overdosage Etc:
Indication-
Advanced or locally advanced breast cancer Adjuvant therapy for postmenopausal women with hormone receptor postive breast cancer
Dosage-
Adult- 2.5mg once daily
